Cytoflavin in Combination With Reperfusion in Stroke Patients

Inclusion Criteria: 1. Signed Informed Consent; 2. Men and women 18-85 y.o.; 3. A diagnosis of "cerebral infarction" has been established and treatment with Cytoflavin® has already been prescribed, or other therapy has been prescribed that does not include Cytoflavin®; 4. NIHSS score of at least 5 and less than 24; 5. reperfusion therapy performed on admission; 6. The size of the ischemic focus according to ASPECTS score \>=6; 7. Time from stroke onset to admission not exceeeding 6 hours; 8. Start of therapy with Cytoflavin® within 24 hours from the onset of stroke (main group); 9. Patients who are able to follow the procedures of the Observational Study Program and strictly follow the doctor's instructions regarding drug therapy. Exclusion Criteria: 1. Individual intolerance or known hypersensitivity to succinic acid, inosine, nicotinamide, riboflavin, or auxiliary components of the drug Cytoflavin®; 2. Hemorrhagic stroke; 3. Contraindications for CT scanning; 4. Initial severe disability requiring assistance in everyday life before stroke; 5. previous stroke with a residual neurological deficit; 6. Severe comorbidity with a life expectancy of less than 6 months; 7. Clinical or laboratory signs of an infectious disease on admission (with the exception of strokes that occurred in COVID-19 convalescents after the first 10 days of illness, and patients with asymptomatic SARS-CoV-2 infection detected during routine examination); 8. Pregnancy or lactation